# MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)

> **NCT05183074** · NA · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 50 (estimated)

## Conditions studied

- Prostate Cancer
- Radiotherapy Side Effect
- Magnetic Resonance-linac
- Stereotactic Ablative RT
- Adaptive Radiotherapy
- Localised Disease
- Oligometastatic Disease

## Interventions

- **DEVICE:** MR-linac

## Key facts

- **NCT ID:** NCT05183074
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05183074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05183074, "MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05183074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*